Clinical trial
A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies
NCT03602079 is registered in ClinicalTrials.gov with Klus Pharma Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies
- Lead sponsor
- Klus Pharma Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- July 16, 2018
- Completion date
- January 12, 2022
- Enrollment
- 49 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.
bile duct cancer, bladder cancer, breast neoplasm malignant primary, cervical cancer, cholangiocarcinoma, colo-rectal cancer, head and neck cancer, head and neck carcinoma, her-2 gene amplification, her2 gene mutation, her2 positive gastric cancer, her2-positive breast cancer, larynx cancer, lip cancer stage i, liver cancer, lung cancer, mouth cancer, mucinous adenocarcinoma gastric, mucinous breast cancer recurrent, mucoepidermoid carcinoma, palate cancer, pancreatic cancer, primary peritoneal carcinoma, prostate cancer, rare diseases, rectal cancer, rectal cancer stage i, rectal cancer stage ii, rectal cancer stage iii, recurrent breast cancer, recurrent colon cancer, recurrent gastric cancer, recurrent ovarian carcinoma, recurrent prostate cancer, recurrent renal cell cancer, salivary gland cancer, salivary gland carcinoma, salivary gland neoplasms, salivary gland tumor, skin cancer, solid tumor, tongue cancer, tonsil cancer, urologic cancer